SOURCE-LINKED STUDY SUMMARY
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Abstract summarizedQuality not appraised
- What was studied
- A double-blind randomized phase 2 trial tested oral zenagamtide versus placebo for glucose control.
- Who / model studied
- 186 adults with type 2 diabetes taking metformin, with or without an SGLT2 inhibitor.
- Studied dose & schedule
- Daily oral treatment titrated to 6, 25 or 50 mg; 36-week intervention.
- What the study found
- Estimated HbA1c reductions were 0.9, 1.3 and 1.4 percentage points; placebo-adjusted differences were 0.5, 0.99 and 1.09 points. Gastrointestinal events affected 26%, 41% and 47%, versus 23% with placebo. Seven active-treatment participants had serious adverse events; none were reported with placebo.
- Limitations & context
- On-treatment efficacy analysis without rescue medication. This oral study cannot inherit injectable weight-loss results. Serious events were reported, not necessarily attributed to treatment.
Read summary source ↗ · Prepared 9/24/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(26)01247-x